|
COMBINE (acamprosate/naltrexone) Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about COMBINE (acamprosate/naltrexone) conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. COMBINE (acamprosate/naltrexone) Clinical research trials and COMBINE (acamprosate/naltrexone) healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as COMBINE (acamprosate/naltrexone). COMBINE (acamprosate/naltrexone) Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a COMBINE (acamprosate/naltrexone) clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their COMBINE (acamprosate/naltrexone) condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > COMBINE (acamprosate/naltrexone)  COMBINE (acamprosate/naltrexone)
COMBINE (acamprosate/naltrexone)
For Condition: Alcoholism
Status: No longer recruiting
Sponsor(s): National Institute on Alcohol Abuse and Alcoholism (NIAAA) ,
Synopsis: Combine is a multicenter, randomized clinical trial that will evaluate combinations of three interventions for treating alcohol dependence. The goal is to determine whether improvement in treatment outcomes can be achieved by various combinations of drug and behavioral interventions. Two of the interventions will consist of pharmacological treatment with naltrexone (Revia) or acamprosate (Campral). The third intervention is a multicomponent behavioral therapy including such components as motivational enhancement therapy, cognitive behavioral therapy, and referral to self-help groups, including AA. All three interventions will include a component supporting compliance to medications and reduction in drinking.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Factorial Assignment, Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: The study has specific inclusion/exclusion criteria that limit participation. To learn more, interested individuals should contact the recruitment coordinator of the site nearest them.
Total Enrollment: 1375
Location and Contact Information:
Southwest Texas Addiction Research and Technology Center, University of Texas Health Science Center
San Antonio, Texas, 78229
United States
University of Miami School of Medicine
Miami, Florida, 33136
United States
Treatment and Research Center, University of Pennsylvania
Philadelphia, Pennsylvania, 19104
United States
Center for Alcohol Programs, Medical University of South Carolina
Charleston, South Carolina, 29425
United States
Addictions Treatment Center, University of Washington
Seattle, Washington, 98108
United States
Harvard University/McLean Hospital
Belmont, Massachusetts, 02478
United States
University of Wisconsin-Milwaukee
Milwaukee, Wisconsin, 53233
United States
Substance Abuse Treatment Unit, Yale University
New Haven, Connecticut, 06511
United States
Roger Williams Medical Center , Brown University
Providence, Rhode Island, 02908
United States
Boston University School of Medicine
Boston, Massachusetts, 02118
United States
Massachusetts General Hospital
Boston, Massachusetts, 02114
United States
Center on Alcoholism, Substance Abuse and Addiction, University of New Mexico
Albuquerque, New Mexico, 87106
United States
Additional Information:
Study ID Numbers: NIAAAComb; U10AA11715,U10AA11777,U10AA11716,U10AA11783,U10AA11773,U10AA11799,U10AA11787,U10AA11727,U10AA11756,U10AA11768,U10AA11776
Study Start Date:
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006206
Other Alcoholism Studies:
1. Naltrexone for Relapse Prevention
2. Behavioral Therapy Plus Naltrexone for Alcoholism
3. Pharmacological Intervention Project (fluoxetine)
4. Ondansetron Treatment for Alcoholism
5. Genetic Factors and Interrelationships for Sexual Orientation, Susceptibility to HIV and Kaposi's Sarcoma, Alcoholism and Psychological Traits, and Histocompatibility Antigens
Related Studies:
Other Alcoholism Clinical Trials
Other Massachusetts Clinical Trials
Other Belmont Clinical Trials
COMBINE (acamprosate/naltrexone)
|
|
|
|
|
|
|
|
